BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Bmab1700 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Bmab1700\, from ClinicalTrials.gov estima
 tes.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07476326-421@assetmemo.bio
DTSTAMP:20261121T005838Z
DTSTART;VALUE=DATE:20270816
DTEND;VALUE=DATE:20270817
SUMMARY:Bmab1700: Phase 1 readout est. (NCT07476326)
DESCRIPTION:Bmab1700\, phase 1.\nStudy: Pharmacokinetics\, Safety\, and Imm
 unogenicity Comparison of Bmab1700 and Opdivo® as Adjuvant Monotherapy in
  Participants With Melanoma\nEstimated primary completion: 16 August 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/bmab1700#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07476326
URL:https://assetmemo.bio/drug/bmab1700#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
